Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab

被引：0
|
作者：
Tovoli, F. [1 ,2 ]
Boe, M. [1 ]
Vivaldi, C. [3 ]
Federico, P. [4 ]
Palloni, A. [5 ]
Dalbeni, A. [6 ,7 ,8 ]
Solda, C. [9 ]
Stefanini, B. [1 ]
Garajova, I. [10 ]
Ielasi, L. [11 ]
De Lorenzo, S. [12 ]
Granito, A. [1 ,2 ]
Stefanini, B. [1 ]
Masi, G. [3 ]
Lonardi, S. [4 ]
Brandi, G. [1 ,5 ]
Daniele, B. [4 ]
Auriemma, A. [7 ,13 ]
Lani, L. [1 ,14 ]
Svegliati-Baroni, G. [15 ]
Campani, C. [16 ]
Piscaglia, F. [1 ,2 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[2] IRCCS Azienda Osped Univ Bologna, Unit Internal Med Hepatobiliary & Immunoallerg Di, Bologna, Italy
[3] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[4] Osped Mare, Med Oncol Unit, Naples, Italy
[5] IRCCS Azienda Osped Univ Bologna, Oncol Unit, Bologna, Italy
[6] Univ Verona, Dept Med, Unit Gen Med C, Verona, Italy
[7] Univ & Hosp Trust AOUI Verona, Verona, Italy
[8] Univ Verona, Liver Unit, Dept Med, Verona, Italy
[9] IRCCS, Veneto Inst Oncol IOV, Oncol Unit 1, Padua, Italy
[10] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[11] Osped Infermi Faenza, Dept Internal Med, Faenza, Italy
[12] Azienda USL Bologna, Oncol Unit, Bologna, Italy
[13] Univ Verona, Sect Innovat Biomed Oncol Area, Dept Engn Innovat Med DIMI, Verona, Italy
[14] IRCCS Azienda Osped Univ Bologna, Unit Semeiot Liver & Alcoholrelated Dis, Bologna, Italy
[15] Polytech Univ Marche, Liver Injury & Transplant Unit, Ancona, Italy
[16] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷
关键词：
D O I：
10.1016/j.dld.2024.01.139
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
F-34
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [21] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
    Yamaba, Shinpei
    Imai, Yukinori
    Sugawara, Kayoko
    Uchida, Yoshihito
    Fuchigami, Akira
    Uchiya, Hiroshi
    Nakayama, Nobuaki
    Mochida, Satoshi
    PLOS ONE, 2024, 19 (04):
  • [22] Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma
    Furusawa, Ai
    Naganuma, Atsushi
    Suzuki, Yuhei
    Hoshino, Takashi
    Yasuoka, Hidetoshi
    Tamura, Yuki
    Naruse, Hiroaki
    Hatanaka, Takeshi
    Kakizaki, Satoru
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (02) : 451 - 459
  • [23] Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma
    Furuichi, Nozomi
    Naganuma, Atsushi
    Kaburagi, Takuya
    Suzuki, Yuhei
    Hoshino, Takashi
    Shibusawa, Nobuyuki
    Horiguchi, Suguru
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Uraoka, Toshio
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 422 - 431
  • [24] TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
    Lei, Jin
    Chen, Bowen
    Song, Meiru
    Zhang, Linzhi
    Zhang, Xinfeng
    Gao, Xiaoqiang
    Li, Yinyin
    Lu, Yinying
    Zuo, Shi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
    Persano, M.
    Rimini, M.
    Foti, S.
    Camera, S.
    Rossari, F.
    Amadeo, E.
    Vitiello, F.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Mascia, L.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2024, 35 : S83 - S83
  • [26] Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma -clinical results show importance of hepatic reserve function
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Kuroda, Hidekatsu
    Yata, Yutaka
    Ohama, Hideko
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Yokohama, Keisuke
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Iijima, Hiroko
    Kaibori, Masaki
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (10) : 624 - 633
  • [27] Operative shortening of the sling as a second-line treatment after TVT failure
    Gibas, Artur
    Matuszewski, Marcin
    Michajlowski, Jerzy
    Krajka, Kazimierz
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2011, 64 (03) : 158 - 160
  • [28] Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
    Personeni, Nicola
    Pressiani, Tiziana
    Zanuso, Valentina
    Casadei-Gardini, Andrea
    D'Alessio, Antonio
    Valgiusti, Martina
    Dadduzio, Vincenzo
    Bergamo, Francesca
    Solda, Caterina
    Rizzato, Mario Domenico
    Giordano, Laura
    Santoro, Armando
    Rimassa, Lorenza
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):
  • [29] Curative therapy after atezolizumab-bevacizumab and role of liquid biopsy in patient selection
    Kulkarni, Anand
    Kumaraswamy, P.
    Sharma, Mithun
    Menon, Balachandran
    Sekaran, Anuradha
    Iyengar, Sowmya
    Alla, Manasa
    Venishetty, Shantan
    Padaki, Nagaraja
    Reddy, Nageshwar
    JOURNAL OF HEPATOLOGY, 2024, 80 : S440 - S440
  • [30] Combining bevacizumab with chemotherapy—from maintenance to second-line treatment
    Alessia Errico
    Nature Reviews Clinical Oncology, 2014, 11 (11) : 621 - 621
12345